Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/14200
Nаziv: | Balancing benefits and risks in the era of biologics | Аutоri: | Adami G. Saag K. Chapurlat R. Guañabens N. Haugeberg G. Lems W. Matijević, Radmila Peel N. Poddubnyy D. Geusens P. |
Dаtum izdаvаnjа: | 1-јан-2019 | Čаsоpis: | Therapeutic Advances in Musculoskeletal Disease | Sažetak: | © The Author(s), 2019. Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab. | URI: | https://open.uns.ac.rs/handle/123456789/14200 | ISSN: | 1759720X | DOI: | 10.1177/1759720X19883973 |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
7
prоvеrеnо 20.11.2023.
Prеglеd/i stаnicа
28
Prоtеklа nеdеljа
7
7
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.